Cargando…
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529672/ https://www.ncbi.nlm.nih.gov/pubmed/23153332 http://dx.doi.org/10.1186/1471-2407-12-524 |
_version_ | 1782253941585608704 |
---|---|
author | Atmaca, Akin Werner, Dominique Pauligk, Claudia Steinmetz, Kristina Wirtz, Ralph Altmannsberger, Hans-Michael Jäger, Elke Al-Batran, Salah-Eddin |
author_facet | Atmaca, Akin Werner, Dominique Pauligk, Claudia Steinmetz, Kristina Wirtz, Ralph Altmannsberger, Hans-Michael Jäger, Elke Al-Batran, Salah-Eddin |
author_sort | Atmaca, Akin |
collection | PubMed |
description | BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (IHC) in paraffin-embedded samples from 357 patients who received chemotherapy in 4 first-line trials. Automated RNA extraction from paraffin and RT-quantitative PCR were additionally used to evaluate EGFR mRNA expression in 130 patients. RESULTS: EGFR protein expression (any grade) and overexpression (3+) were observed in 43% and 11% of patients, respectively. EGFR positivity correlated with intestinal type histology (p = 0.05), but not with other clinicopathologic characteristics. Median follow-up was 18.2 months. Median overall survival (OS) was similar in patients with EGFR positive vs. those with EGFR negative tumors, regardless whether positivity was defined as ≥1+ (10.6 vs. 10.9 months, p = 0.463) or as 3+ (8.6 vs. 10.8 months, p = 0.377). The multivariate analysis indicated that EGFR status is not an independent prognostic factor (hazard ratio 0.85, 0.56 to 1.12, p = 0.247). There were also no significant differences in overall survival when patients were categorized according to median (p = 0.116) or quartile (p = 0.767) distribution of EGFR mRNA gene expression. Similar distributions of progression-free survival according to EGFR status were observed. CONCLUSIONS: Unlike different cancer types where EGFR-positive disease is associated with an adverse prognostic value, EGFR positivity is not prognostic of patient outcome in metastatic gastric or GE cancer. |
format | Online Article Text |
id | pubmed-3529672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35296722013-01-03 The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer Atmaca, Akin Werner, Dominique Pauligk, Claudia Steinmetz, Kristina Wirtz, Ralph Altmannsberger, Hans-Michael Jäger, Elke Al-Batran, Salah-Eddin BMC Cancer Research Article BACKGROUND: The epidermal growth factor receptor (EGFR) is a potential target of anticancer therapy in gastric cancer. However, its prognostic role in metastatic gastric or gastroesophageal junction (GE) cancer has not been established yet. METHODS: EGFR status was analyzed by immunohistochemistry (IHC) in paraffin-embedded samples from 357 patients who received chemotherapy in 4 first-line trials. Automated RNA extraction from paraffin and RT-quantitative PCR were additionally used to evaluate EGFR mRNA expression in 130 patients. RESULTS: EGFR protein expression (any grade) and overexpression (3+) were observed in 43% and 11% of patients, respectively. EGFR positivity correlated with intestinal type histology (p = 0.05), but not with other clinicopathologic characteristics. Median follow-up was 18.2 months. Median overall survival (OS) was similar in patients with EGFR positive vs. those with EGFR negative tumors, regardless whether positivity was defined as ≥1+ (10.6 vs. 10.9 months, p = 0.463) or as 3+ (8.6 vs. 10.8 months, p = 0.377). The multivariate analysis indicated that EGFR status is not an independent prognostic factor (hazard ratio 0.85, 0.56 to 1.12, p = 0.247). There were also no significant differences in overall survival when patients were categorized according to median (p = 0.116) or quartile (p = 0.767) distribution of EGFR mRNA gene expression. Similar distributions of progression-free survival according to EGFR status were observed. CONCLUSIONS: Unlike different cancer types where EGFR-positive disease is associated with an adverse prognostic value, EGFR positivity is not prognostic of patient outcome in metastatic gastric or GE cancer. BioMed Central 2012-11-15 /pmc/articles/PMC3529672/ /pubmed/23153332 http://dx.doi.org/10.1186/1471-2407-12-524 Text en Copyright ©2012 Atmaca et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Atmaca, Akin Werner, Dominique Pauligk, Claudia Steinmetz, Kristina Wirtz, Ralph Altmannsberger, Hans-Michael Jäger, Elke Al-Batran, Salah-Eddin The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
title | The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
title_full | The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
title_fullStr | The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
title_full_unstemmed | The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
title_short | The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
title_sort | prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529672/ https://www.ncbi.nlm.nih.gov/pubmed/23153332 http://dx.doi.org/10.1186/1471-2407-12-524 |
work_keys_str_mv | AT atmacaakin theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT wernerdominique theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT pauligkclaudia theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT steinmetzkristina theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT wirtzralph theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT altmannsbergerhansmichael theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT jagerelke theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT albatransalaheddin theprognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT atmacaakin prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT wernerdominique prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT pauligkclaudia prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT steinmetzkristina prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT wirtzralph prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT altmannsbergerhansmichael prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT jagerelke prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer AT albatransalaheddin prognosticimpactofepidermalgrowthfactorreceptorinpatientswithmetastaticgastriccancer |